The efficient and targeted delivery of genes and other impermeable therapeutic molecules into retinal cells is of immense importance for therapy of various visual disorders. Traditional methods for gene delivery require viral transfection, or chemical methods that suffer from one or many drawbacks such as invasiveness, low efficiency, lack of spatially targeted delivery, and can generally have deleterious effects such as unexpected inflammatory responses and immunological reactions. Here, we introduce a continuous wave near-infrared laser-based Nano-enhanced Optical Delivery (NOD) method for spatially controlled delivery of opsin-encoding genes into retina in-vivo. In this method, the optical field enhancement by gold nanorods is utilized to transiently permeabilize cell membrane enabling delivery of exogenous impermeable molecules to nanorod-binding cells in laser-irradiated regions. The successful delivery and expression of opsin in targeted retina after in-vivo NOD in the mice models of retinal degeneration opens new vista for re-photosensitizing retina with geographic atrophies as in dry age-related macular degeneration (AMD).
Introduction
Dry age-related macular degeneration (Dry-AMD) involving dysfunction of retina is characterized by degeneration of photoreceptors. The degree of visual loss increases with ageing and this is a major concern for our demographic changes towards elderly population. The eye offers an excellent target for gene therapy (replacement of defective genes with new functional genes) because it is easily accessible and relatively immune privileged. Most of the current clinical ophthalmic treatments using gene 1 , RNA aptamer 2 and shRNAs 3 for therapeutic benefits are utilizing viral vectors, which suffers from drawbacks such as low efficiency, unexpected inflammatory responses, especially innate and immune barriers 4 , toxicity 5 , and potential recombination of or complementation in vivo which can generate virulent viral pathogens after vector delivery 6 . In addition, limitation on size of plasmid that can be packaged by the mostcommonly used safe (AAV) virus vectors 7, 8 may create hindrance to deliver novel gene-editing large molecules such as CRISPR/Cas9 for visual disorders. Furthermore, the ability to deliver therapeutic genes into spatially targeted higher order retinal neurons of degenerated retina (e.g. geographic atrophic
areas of macula in AMD [9] [10] [11] [12] [13] ) is advantageous, for example in optogenetic activation therapy. Therefore, there have been significant efforts in developing alternative, non-viral methods such as physical (electroporation 14, 15 , ultrasound 16 etc.) and chemically-mediated (e.g. biodegradable polymer 17, 18 ) methods 19, 20 .
These methods also suffer from one or more drawbacks, such as invasiveness, reduced efficiency, lack of spatially-targeted delivery and/or having several deleterious effects on transfected cells 21 . The advent of optoporation by focused ultrafast near infrared laser microbeam has allowed mitigating the drawbacks of these methods. Recently, we demonstrated use of near IR laser microbeam for delivery of impermeable molecules to neurons 22 , opsin-encoding genes to cells 23 and localized areas of the retina 24 .
However, the extreme difficulties in maintaining tight focus inside tissue and requirement of high peak power to create holes in the cell membrane, has limited the use of laser-based delivery to small animal applications 25 . Therefore, there is an imminent need for development and optimization of new and efficient non-viral method that can deliver therapeutic molecules irrespective of their size to spatially targeted regions of retina in a minimally invasive manner.
Recently, optogenetic therapies have been evaluated for vision restoration in mice models of retinal degeneration either by non-specific stimulation of retina 26 or in a cell-specific manner for retinal ganglion cells [27] [28] [29] [30] [31] and ON bipolar cells [32] [33] 34 . Further, use of chloride-channel opsin (NpHR) expressing in longerpersisting cone photoreceptor protein has shown promise for restoration of vision 35 . The primary method for delivery of opsin-encoding genes to adult retina employs viral transfection which has high transduction efficiency and persistent gene expression 36 . Both non-specific transfection of the retina as well as 4 promoter-specific targeting of retinal ganglion cells of adult mice and rats using viral methods have been successful 27-30, 32-33, 37-38 . However, clinical translation of optogenetic activation for vision restoration has a major challenge: (i) requirement of external activation light or opsin with significantly higher sensitivity to ambient light; and (ii) method to optogenetically treat only those areas of the retina that have undergone degeneration rather than the whole retina. Effective therapy of visual disorders involving geographic atrophies of the retina requires localized delivery of the targeted molecules to specific retinal cells in atrophied regions.
Herein, we introduce use of nano-enhancement of near-infrared optical field of continuous wave (CW) near-infrared (NIR) laser beam by surface plasmon resonance (SPR) near targeted retinal cells for gene delivery. To allow ambient-light based activation 34 , we utilized multi-characteristic-opsin (MCO) encoding plasmids to sensitize retinal cells in degenerated retina. It would be highly desirable to reinduce transgene expression by reinjection, and NOD provides this opportunity.
Materials and Methods

Ethics statement
All experimental procedures were conducted according to the Nanoscope Technologies-Institutional Animal Care and Use Committee approved protocol.
Construction, and Purity of plasmid
Double stranded DNA fragment coding for multi characteristic opsin-II (MCO-II) was synthesized using high throughout DNA synthesizer. The restriction enzyme sites (BamH1 and Sal1) were added to the ends of the DNA fragment by PCR amplifying using the corresponding primers. Afterwards, the fragment with BamH1/Sal1 sites was inserted to the BamH1/Sal1 site of the pAAV vector. Thus, a plasmid was created comprising a CAG promoter, MCO-II and reporter (mCherry). Prior to the experiments, the plasmid was digested by restriction enzymes (BamH1 and Sal1) to verify the size and purity using 0.8% agarose gel electrophoresis.
Theoretical structure prediction
Raptor-X used for predicting the 3-D structure of MCO-II. The program uses a conditional neural fields (CNF), a variant of conditional random fields and multiple template treating procedure to develop the predicted structure of MCO-II gene.
2.3 Sensitizing/functionalizing gold nanorods to optical delivery beam and cells
The aspect ratio (ratio of size of short axis to long axis) of gold nanorods (GNRs) can vary from 1:1 to 1:5 to result in Surface plasmon resonance (SPR) peak varying from visible (~530 nm) to NIR (~1100 nm). Gold nanorods (diameter: 10 nm, length: 40 nm) with plasmon absorption maximum at 800 nm were used for NOD experiments. For specific membrane binding, gold nanorods were incubated with 4µM Concanavalin A at 37 ᵒC (Overnight). The unbound ConA molecules were removed by centrifugation at 13,000 rpm for 10 min. The ConA conjugated GNR were then resuspended into 10mM HEPES buffer pH (7.2). Gold nanorods (diameter: 10 nm, length: 40 nm) with SPR maximum at 808 nm was used for NOD optimization.
Patch-clamp recording setup
The MCO-II opsin is activatable over a broad visible-light spectral range (400 to 700nm). To determine the light dependent inward photocurrent, the MCO-II expressing cells were exposed to pulses (500 The cultures were maintained at 37 ᵒC in a humidified 5% CO2 atmosphere. Prior to the NOD experiments, the cells were incubated with ConA functionalized GNR for two hours at 37ᵒ C in a humidified 5% CO2 incubator. Purified plasmid (CAG-MCO-II-mCherry) was added in the cell culture medium and incubated for 15 min at 37 ᵒC in a humidified 5% CO2 incubator. After 15 minutes of incubation, NOD was carried out using CW laser (800 nm). At least 6 eyes were used for in-vitro and in-vivo NOD experiments. Retinal degenerated mice (rd10:
/J) were obtained from Jackson laboratory and bred in the animal facilities of the Nanoscope. Once the animals were acclimated to the animal facility for ~1 week, they were anesthetized with 90 mg/kg ketamine, 10 mg/kg xylazine acepromazine (0.5 mg/kg). In all experiments attention was paid to the ethical guidelines for investigations of experimental pain in conscious animals, and the procedures were approved by the IACUC.
Retinal explant
Adult rd10 deficient mice were sacrificed using CO2. The eyes of rd10 mice were surgically removed from its muscles and remaining orbital contents and then choroid, sclera, cornea, lens, vitreous were the removed from enucleated eye. The remaining retina was incubated with fresh Neurobasal media. The RPE was gently removed from retina and retinal explants then cut into pieces using a tissue chopper.
With the photoreceptor side down, the explants were placed onto sterilized petri-dishes previously coated with 5ug/dish of Poly-D-Lysine containing 1ml of Neurobasal media. The explants were incubated with ConA conjugated GNR for 2hr at 37 ᵒC in a humidified 5% CO2 incubator. The CAG-MCO-IImCherry plasmid was placed directly on the retinal surface for 15 min and explants were then exposed with 800nm CW laser for 30 sec., the GNRs are functionalized with ConA.
2.8 Transduction of MCO-II-mCherry into rd10 mouse retina
Adult (8 weeks old) rd10 mice were treated humanely in strict compliance with IACUC on the use of animals in research. The rd10 mice (N=3) were anesthetized with a mixture of ketamine (65 mg/kg), xylazine (7.5 mg/kg), and acepromazine (0.5 mg/kg). One drop of local anesthesia (0.5% proparacaine hydrochloride) was instilled into both the eyes of the animals. Functionalized gold nanorods and MCO-II-mCherry plasmids was injected into one of the eyes by a sterilized 32-G needle of a Hamilton microsyringe inserted through the sclera into the vitreous cavity. As a negative control, the other eye was intravitreally injected with same volume of PBS. 1% Tropicamide ophthalmic solution was applied for dilating the pupil. The cornea was kept moist with a balanced salt solution during the entire surgical procedure. Schematic of experimental procedure for in-vivo NOD is shown in Fig. 4a . NOD using CW laser was carried out with the in-vivo set up (Fig. 4b) . After 1 week of transfection, the animals were euthanized, and retinal tissue explanted. Using confocal microscope (Fluoview FV1000) for mCherry expression, the expression level (fluorescence intensity) of these cells were quantified. Image processing was performed by using NIH ImageJ software.
Fourier domain optical coherence tomography system
FD-OCT is based on spectral domain implementation of the OCT system developed in the OCT research community [39] [40] [41] [42] [43] [44] , and has been in clinical Ophthalmology practice. In the FD-OCT, reference mirror is not scanned to perform depth scan. The reference mirror is stationary. The interference signal between the reflected intensities from the reference mirror and the sample microstructures is detected with a spectrometer as a function of wavelength. The detected signal (as a function of wavelength) is then Fourier transformed to obtain intensity profile as a function of depth. FD-OCT scans the whole depth of the sample without any mechanical scanning. We performed SD-OCT imaging as described previously [45] [46] [47] .
Prior to imaging, mice were anesthetized. Mice were placed on the platform of the SD-OCT and retinal thickness measurements were made.
Statistics
GraphPad Prism was used to analyze data. The data were plotted as mean ± S. D. Statistical significant difference analyses were carried out by t-test. P < 0.05 was considered statistically significant.
Results
Improvement of optokinetic response in MCO-II transfected rd10
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The ) is shown in Fig. 2f . The peak photocurrent generated in MCO-II expressing cells was found to be 300 pA. While the on-rate of induced photocurrent in MCO-II expressing cells in response to the light was in ms range, the off rate (decay of current in absence of light) was found to be significantly higher.
Nano-enhanced optical delivery of opsin-plasmids into retina explant
We utilized NOD parameters optimized (in HEK cells) for spatially targeted delivery of MCO-IImCherry plasmids into retina explants. The explants were incubated for 1hr with ConA-conjugated GNRs having peak absorption at 800 nm. Confocal fluorescence image of retinal explant (Fig. 3a) shows reporter-mCherry expression in targeted area (marked by square) 2 days after exposure to CW NIR laser beam (800 nm). Fig. 3b shows cellular expression in the targeted area of the explant. The nontargeted areas (Fig. 3c) showed basal level of autofluorescence. To quantify the relative expression of mCherry in cell membrane and intracellular components, intensity profiles along line drawn across the cells are plotted (Fig. 3d) . The MCO-II expression in plasma membrane was found to be significantly , exposure time: 30 sec). 1 µl of 1: 1 mixture of ConA-functionalized GNRs and MCO-IImCherry plasmids was injected intravitreally into rd10 mice eye to result in final concentration of 500 ng/ml and 30 ng/ml respectively for GNRs and MCO-II-mCherry plasmids. After dilation, the CW NIR laser beam was applied for 30 seconds on the eye (Fig. 4b) . Fig. 4c shows the zoomed image of an eye during the NOD laser exposure. The image of fundus with the NOD laser irradiation spot (red) is shown in Fig. 4d . 7 days after intravitreal injection and NOD, the mice were sacrificed, and retinal cup extracted and imaged using confocal fluorescence microscopy. While the non-targeted regions did not show reporter (mCherry) fluorescence (Fig. 4e ), significant expression of reporter fluorescence in NODtargeted retinal area(s) was observed (Figs. 4 f, g ). Comparison of fluorescence intensity of mCherry in targeted and non-targeted regions of retina is shown in Fig. 4h . The retina of non-NOD control eye did not show any characteristic (mCherry) fluorescence. Suppl. Fig. 2 shows cellular expression of mCherry in retina extracted after in-vivo NOD of MCO-II-mCherry. Suppl. Fig. 2b shows the intensity profiles along lines drawn through retinal cells (in Supp. . Therefore, we evaluated structural integrity of retinal tissue and other ocular elements (cornea, lens) after injection (Suppl. Fig. 3 a, b) . In order to characterize any damage due to NOD laser beam irradiation, the cornea and retina was imaged after NOD (Suppl. Fig. 3 c, d ). Comparison of retinal thickness (No injection vs. After injection before NOD vs. After NOD) shows integrity of the retina is not compromised after NOD (Suppl. Fig. 3e ).
MCO-II sensitized RGCs after NOD are functionally activatable by white-light
Functional response of the MCO-II expressing RGCs (in explant, delivered by NOD) toward whitelight stimulation was determined by multi-electrode array electrophysiology (Fig. 5a ). Different light intensities were used to stimulate MCO-II expressing RGCs. Fig. 5b shows representative spiking activities in MCO-II transfected RGCs (after NOD) with and without light. With increase in light intensity the spiking rate increased (Fig. 5c ).
Discussion
Patient-to-patient variability and time-dependent changes in spatial-distribution of retinaldegeneration demands site-specific molecular delivery for effective therapeutic outcome. For example, in case of dry-AMD, spatially targeted delivery of opsin-encoding gene is required in macula, which loses photosensitivity due to loss of photoreceptors [48] [49] [50] . With viral or other non-viral (e.g. electroporation, lipofection) method, the opsin-genes will be delivered everywhere, causing uncontrolled expression over the whole retina. This will cause complications in functioning of non-degenerated areas of retina 51 .
The spatially targeted delivery into regions of degenerated retina can be achieved using NOD by shining the NIR laser beam in targeted areas. The efficient localized field enhancement by gold nanostructures [52] [53] [54] [55] [56] [57] [58] [59] [60] in For example, in glaucoma and ischemic retinopathy one need to target RGCs, microglia, astrocytes, and invading macrophages [62] [63] . By varying shape of functionalized field-enhancing gold nanorods that binds to targeted cell types, tuning the NIR laser wavelength will allow wavelength-selective enhancement near specific cells and thus, selective delivery.
In NOD method, the contrast in temperature rise in laser-irradiated nanorod-attached cells at nanohotspots is significant enough to allow site-specific delivery of large (MCO-II-mCherry) plasmids. The NOD approach based on CW NIR laser beam is found to be minimally invasive with no detectable col-lateral damage to retina or other ocular elements as measured by OCT. Further, the gold nanorods have very low cytotoxicity and have been used in clinical trials. In case of rapid movement of eye in clinical practice, it may be advantageous to use a spatially sculpted NIR beam to match the shape of the region(s) of interest in the tissue requiring targeted molecular delivery by NOD. Shaping the NIR laser beam for NOD can be achieved by use of digital micromirror device (DMD) or spatial light modulator (SLM) to fit the targeted regions (e.g., geographic atrophies of retina in degenerative diseases) so that the therapeutic molecules (e.g. genes) can be delivered in a high throughput manner.
Conclusions
The in-vitro and in-vivo results, presented here using NOD, clearly demonstrate in-vivo gene delivery and functional cellular expression in targeted regions of retina using CW NIR laser beam without compromising structural integrity of the eye. Our results show that significant photocurrent can be reliably generated in MCO-II sensitized cells at white light intensity level close to ambient light condition. We believe our method of non-viral delivery of gene encoding opsins will pave the way for clinical applications in treatment of patients with retinal dystrophies.
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